Compare BRAG & MIRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BRAG | MIRA |
|---|---|---|
| Founded | 2018 | 2020 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Office Equipment/Supplies/Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 41.9M | 43.7M |
| IPO Year | 2021 | 2023 |
| Metric | BRAG | MIRA |
|---|---|---|
| Price | $1.60 | $1.01 |
| Analyst Decision | Hold | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $6.00 | N/A |
| AVG Volume (30 Days) | 45.2K | ★ 118.9K |
| Earning Date | 05-14-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $6.67 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.42 | $0.90 |
| 52 Week High | $4.78 | $2.45 |
| Indicator | BRAG | MIRA |
|---|---|---|
| Relative Strength Index (RSI) | 38.98 | 47.12 |
| Support Level | $1.45 | $0.99 |
| Resistance Level | $2.23 | $1.22 |
| Average True Range (ATR) | 0.15 | 0.07 |
| MACD | -0.01 | 0.00 |
| Stochastic Oscillator | 29.96 | 25.90 |
Bragg Gaming Group Inc is predominantly a B2B online gaming technology platform and casino content aggregator. The company's proprietary studios offer high-performing, data-driven casino gaming titles from in-house brands Wild Streak, Spin, Atomic Slot Lab, Indigo Magic, and Oryx Gaming. It offers a full range of games including slot games, table games, card games, video bingo, scratch card games, virtual sports, and live dealer games which are featured on the company's PAM platform and also available for use on other gaming platforms offered by third parties. Geographically, the company generates a majority of its revenue from Malta, and the rest from Netherlands, Curacao, the United States, Croatia, Marshall Islands, Brazil, Isle of Man, Belgium, Czech Republic, and other regions.
Mira Pharmaceuticals Inc is a clinical-stage pharmaceutical development company focused on developing novel oral small-molecule therapeutics for neurologic, neuropsychiatric, metabolic, and inflammatory disorders. The company's pipeline includes three product candidates: Ketamir-2, MIRA-55, and SKNY-1, three drug candidates designed to address unmet medical needs across neuropathic and inflammatory pain, central nervous system disorders, and metabolic and behavioral conditions. The company operates as a single operating and reportable segment.